79 results
424B5
NBSE
NeuBase Therapeutics Inc
30 Jun 23
Prospectus supplement for primary offering
8:42am
candidates depends upon their market acceptance among physicians, patients, healthcare payors and the medical community.
Even if our product candidates … obtain regulatory approval, our products, if any, may not gain market acceptance among physicians, patients, healthcare payors and the medical community
8-K
EX-99.1
NBSE
NeuBase Therapeutics Inc
11 May 23
NeuBase Reports Business Update and Financial Results for the First Quarter of 2023
4:20pm
pipeline expected to be provided during 2023.
Gene Editing Research Agreements:
The Company’s previously announced collaboration with a global healthcare … company to evaluate the PATrOL™ platform for three monogenic genetic diseases remains on track. The global healthcare company will have the exclusive
424B5
NBSE
NeuBase Therapeutics Inc
29 Dec 22
Prospectus supplement for primary offering
5:03pm
with a global healthcare company, pursuant to which such global healthcare company will evaluate the Company’s PATrOL™ platform for three monogenic genetic … , healthcare payors and the medical community.
Even if our product candidates obtain regulatory approval, our products, if any, may not gain market acceptance
8-K
EX-99.1
tllqytdl4 ni
21 Dec 22
NeuBase Therapeutics Reports Business Update and Financial Results
8:10am
8-K
5q06qqz6or0uytd8o3f
29 Jun 22
NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO
8:03am
8-K
EX-99.1
nimr rkqansb
29 Jun 22
NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO
8:03am
424B5
t04i7x9nalcd q34
27 Aug 21
Prospectus supplement for primary offering
5:21pm
8-K
EX-1.1
j4s9 96m5rb
27 Aug 21
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
36ek795gpmz41 ym7qxx
12 Aug 21
NeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating Highlights
4:18pm
8-K
EX-99.1
9w8dwfdfog
13 May 21
NeuBase Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2021
4:32pm
8-K
EX-99.1
wu1xl3r4jrv
12 May 21
NeuBase Therapeutics Appoints Gerald J. McDougall to Board of Directors
4:30pm
8-K
fmvhxx75go2y0usu
12 May 21
NeuBase Therapeutics Appoints Gerald J. McDougall to Board of Directors
4:30pm
424B5
66bqerm1mee4a3v
23 Apr 21
Prospectus supplement for primary offering
4:05pm